Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1 -familial platelet disorder
Science Translational Medicine · 08.01.2025 · 17 (780)
DOI: 10.1126/scitranslmed.adn9832 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 08.01.2025. Verfasst von Mona Mohammadhosseini und 25 weiteren Autor:innen. Beteiligte Einrichtung: Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Signal Transduction, Inflammation, Blood Platelet Disorders. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Familial platelet disorder (FPD) is associated with germline RUNX1 mutations, establishing a preleukemic state and increasing the risk of developing leukemia. Currently, there are no intervention strategies to prevent leukemia progression. Single-cell RNA sequencing ( n = 10) combined with functional analysis of samples from patients with RUNX1 -FPD ( n > 75) revealed that FPD hematopoietic stem and progenitor cells (HSPCs) displayed increased myeloid differentiation and suppressed megakaryopoiesis because of increased activation of prosurvival and inflammatory pathways. Bone marrow from patients with RUNX1 -FPD contained an elevated cytokine milieu, exerting chronic inflammatory stress on HSPCs. RUNX1 -FPD HSPCs were myeloid biased, had increased self-renewal, and were resistant to inflammation-mediated exhaustion. The bone marrow from patients with RUNX1 -FPD showed high transcript and protein expression of CD74 at the preleukemic stage compared with that of healthy controls, which remained high upon patient transformation into leukemia. Further, CD74-mediated signaling was exaggerated in RUNX1 -FPD HSPCs compared with healthy controls, leading to the activation of mTOR and JAK/STAT pathways with increased cytokine production. Genetic and pharmacological targeting of CD74 with ISO-1 and its downstream targets JAK1/2 and mTOR reversed RUNX1 -FPD differentiation defects in vitro and in vivo and reduced inflammation. Our results highlight that inflammation is an early event in RUNX1 -FPD pathogenesis, and CD74 signaling is one of the drivers of this inflammation. The repurposing of JAK1/2i (ruxolitinib) and mTORi (sirolimus) and promoting the advancement of CD74 inhibitors in clinical settings as an early intervention strategy would be beneficial to improve the phenotype of patients with RUNX1 -FPD and prevent myeloid progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
- Division of Oncological Sciences, Oregon Health & Science University, Portland, OR 97239, USA.
- Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA.
- Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
- Oncogenesis and Development Section, Division of Intramural Research, National Human Genome Research Institute, Bethesda, MD 20894, USA.
- Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
ORCID-Profile: Mona Mohammadhosseini, Trevor Enright, Adam Duvall, Hsin-Yun Lin, Aysegul Ors, Brett A Davis, Ana Catarina Menezes, Matthew Merguerian, Shawn Chong, Natalie T Deuitch, Shira Glushakow-Smith, Kira Gritsman, Marshall S Horwitz, Sioban Keel, Lucio H Castilla, Emek Demir, Paul Liu, Anupriya Agarwal
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Mohammadhosseini, M., Enright, T., Duvall, A., Chitsazan, A., Lin, H. Y., Ors, A., Davis, B. A., Nikolova, O., Bresciani, E., Diemer, J., Craft, K., Menezes, A. C., Merguerian, M., Chong, S., Calvo, K. R., Deuitch, N. T., Glushakow-Smith, S., Gritsman, K., Godley, L. A., …, & Agarwal, A. (2025). Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1 -familial platelet disorder. Science Translational Medicine, 17(780). https://doi.org/10.1126/scitranslmed.adn9832
Vancouver
Mohammadhosseini M, Enright T, Duvall A, Chitsazan A, Lin HY, Ors A, et al. Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1 -familial platelet disorder. Science Translational Medicine. 2025;17(780). doi:10.1126/scitranslmed.adn9832
BibTeX
@article{Mohammadhosseini2025,
author = {Mohammadhosseini, Mona and Enright, Trevor and Duvall, Adam and Chitsazan, Alex and Lin, Hsin-Yun and Ors, Aysegul and Davis, Brett A and Nikolova, Olga and Bresciani, Erica and Diemer, Jamie and Craft, Kathleen and Menezes, Ana Catarina and Merguerian, Matthew and Chong, Shawn and Calvo, Katherine R and Deuitch, Natalie T and Glushakow-Smith, Shira and Gritsman, Kira and Godley, Lucy A and Horwitz, Marshall S and Keel, Sioban and Castilla, Lucio H and Demir, Emek and Mohammed, Hisham and Liu, Paul and Agarwal, Anupriya},
title = {Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1 -familial platelet disorder},
journal = {Science Translational Medicine},
year = {2025},
volume = {17},
number = {780},
doi = {10.1126/scitranslmed.adn9832}
}
EUVIMED